HK Stock Market Move | EDGE MEDICAL-B (02675) rises nearly 8% again as the domestic market accelerates the adoption of domestic alternatives to Da Vinci, and the company's overseas installations begin to ramp up.

EDGE MEDICAL-B (02675) rose nearly 8% again, and as of the time of writing, it is up 6.83%, priced at HKD 41.3, with a transaction volume of HKD 22.9571 million. In news, Jingfeng Medical recently announced that it has completed an investment in the AI company Yuanhao Power. This investment will further enhance the companys strength in exploring the "AI + surgical Siasun Robot & Automation" intelligent surgery field, laying a strategic foundation for its embodied intelligent medical Siasun Robot & Automation business. Yuanhao Power focuses on the fifth-generation multimodal 4D world model and was founded by a team with a background from Tsinghua University, directly aligning its technology with "AI + surgical Siasun Robot & Automation" embodied intelligence. Huachuang Securities pointed out that in the domestic market, Jingfeng Medical holds a leading position among domestic manufacturers, maintaining the largest share in the number of bids won. With the implementation of policies such as domestic service pricing projects and provincial-level centralized procurement of equipment, the market penetration rate for domestic endoscopic surgery Siasun Robot & Automation is expected to rise rapidly. Domestic manufacturers such as Jingfeng are likely to accelerate their domestic substitution for Da Vinci, thanks to their price advantages. In overseas markets, the company's installations have already begun to ramp up, and its overseas support service system is gradually improving. Combined with the cost-performance advantages of its products, the company has significant potential in non-U.S. overseas markets.